Thyroid

Treatment

DTC

END0021
Phase III Cabozantinib (XL184) in Radiiodine-Refractory Differentiated Thyroid Cancer

PI: Colevas
Sponsor: Exelixis

ATC/UTC

END0023
Aberamiclib in metastatic or locally advanced Anaplastic /Undifferentiated Thyroid Cancer

PI: Khan
Stanford

KEY

- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold